Ultragenyx Q4 revenue rises 25% amid restructuring

Ultragenyx Pharmaceutical

12/02/2026 21:10

Overview

Biopharmaceutical firm's Q4 2025 revenue grew 25% yr/yr

Company initiated a strategic restructuring plan, reducing headcount by 10%

2026 revenue expected to rise 8% to 13% from 2025

Outlook

Ultragenyx expects 2026 revenue between $730 mln and $760 mln

Company aims for profitability in 2027 through strategic restructuring

Result Drivers

CRYSVITA GROWTH - Crysvita revenue grew 17% in 2025, driven by strong sales in Latin America and Türkiye

EVKEEZA DEMAND - Evkeeza revenue rose 84% in 2025, reflecting increased demand following international launches

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$1.29
Q4 Net Income
-$129 mln
Q4 Operating Expenses
$321 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $61.50, about 157.5% above its February 11 closing price of $23.88

Press Release: ID:nGNX88ZDMT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)